These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16462058)

  • 1. Indoline derivatives I: synthesis and factor Xa (FXa) inhibitory activities.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Matsui Y; Fujimoto K
    Chem Pharm Bull (Tokyo); 2006 Feb; 54(2):163-74. PubMed ID: 16462058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoline derivatives II: synthesis and factor Xa (FXa) inhibitory activities.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Ozeki T; Fujimoto K
    Chem Pharm Bull (Tokyo); 2007 Mar; 55(3):393-402. PubMed ID: 17329879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinnamyl derivatives: synthesis and factor Xa (FXa) inhibitory activities.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
    Chem Pharm Bull (Tokyo); 2008 Jun; 56(6):758-70. PubMed ID: 18520077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
    Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1494-504. PubMed ID: 17917295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
    Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1.
    Schweinitz A; Stürzebecher A; Stürzebecher U; Schuster O; Stürzebecher J; Steinmetzer T
    Med Chem; 2006 Jul; 2(4):349-61. PubMed ID: 16848746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
    Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
    Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
    Han Q; Dominguez C; Stouten PF; Park JM; Duffy DE; Galemmo RA; Rossi KA; Alexander RS; Smallwood AM; Wong PC; Wright MM; Luettgen JM; Knabb RM; Wexler RR
    J Med Chem; 2000 Nov; 43(23):4398-415. PubMed ID: 11087565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
    Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
    J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
    Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.
    Yang J; Su G; Ren Y; Chen Y
    Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Niitsu Y; Asai F; Ishizuka T; Fujimoto K
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):22-33. PubMed ID: 19122312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
    Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition.
    Nishida H; Miyazaki Y; Mukaihira T; Shimada H; Suzuki K; Saitoh F; Mizuno M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):459-62. PubMed ID: 15056966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
    Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
    Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
    Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
    Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.